Caribou Biosciences (CRBU) Research & Development (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Research & Development of $20.6 million for Q1 2026, down 41.99% year-over-year from $35.5 million in Q1 2025, and down 13.45% quarter-over-quarter from $23.8 million in Q4 2025.
Caribou Biosciences (CRBU) Research & Development (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Research & Development for 7 consecutive years, with $20.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 41.99% year-over-year to $20.6 million; the TTM figure through Mar 2026 stood at $94.5 million (down 28.34% YoY), while the FY2025 annual figure was $109.4 million, down 15.92% from the prior year.
- Research & Development declined to $20.6 million in Q1 2026 per CRBU's latest filing, from $23.8 million in the prior quarter.
- Across five years, Research & Development topped out at $35.5 million in Q1 2025 and bottomed at $13.9 million in Q1 2022.
- Historically, Research & Development has averaged $26.7 million across 5 years, with a median of $26.5 million in 2023.
- Annual changes were most pronounced in 2023 — Research & Development surged 84.64% — and 2026, when it plunged 41.99%.
- Caribou Biosciences' Research & Development stood at $25.7 million in 2022, then rose by 21.54% to $31.3 million in 2023, then retreated by 2.61% to $30.5 million in 2024, then dropped by 21.83% to $23.8 million in 2025, then decreased by 13.45% to $20.6 million in 2026.
- Business Quant data shows CRBU's Research & Development at $20.6 million in Q1 2026, $23.8 million in Q4 2025, and $22.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Caribou Biosciences | 163.09 Mn | 50.78 Mn | - | 18.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.94 Mn |
| Mar 31, 2026 | 20.61 Mn |
| Dec 31, 2025 | 23.82 Mn |
| Sep 30, 2025 | 22.40 Mn |
| Jun 30, 2025 | 27.69 Mn |
| Mar 31, 2025 | 35.53 Mn |
| Dec 31, 2024 | 30.46 Mn |
| Sep 30, 2024 | 30.42 Mn |
| Jun 30, 2024 | 35.48 Mn |
| Mar 31, 2024 | 33.79 Mn |
| Dec 31, 2023 | 31.28 Mn |
| Sep 30, 2023 | 28.58 Mn |
| Jun 30, 2023 | 26.50 Mn |
| Mar 31, 2023 | 25.71 Mn |
| Dec 31, 2022 | 25.74 Mn |
| Sep 30, 2022 | 19.99 Mn |
| Jun 30, 2022 | 22.58 Mn |
| Mar 31, 2022 | 13.92 Mn |
| Dec 31, 2021 | 15.11 Mn |
| Sep 30, 2021 | 15.83 Mn |